EQT X to acquire Adalvo, a rapidly growing, asset-light B2B dossier developer providing market-approval-ready generic drug dossiers to pharmaceutical companies
EQT will support Adalvo's next phase of growth, further investing in R&D and innovation, and advancing the operational scale-up of the business
Adalvo is uniquely positioned as a one-stop partner, combining strong business development capabilities with a flexible, customer-centric model to meet the bespoke needs of pharmaceutical companies worldwide
Adalvo plays an important role in increasing access to affordable healthcare by developing and distributing generic drugs at affordable prices across a wide range of markets. The transaction highlights EQT's commitment to partnering with companies that deliver critical services to society

STOCKHOLM, July 18, 2025 /PRNewswire/ -- EQT X ("EQT") has agreed to acquire a majority stake in Adalvo (the "Company"), a leading asset-light B2B dossier developer. Existing shareholders, including Aztiq, the holding company of Adalvo's current Chairman Róbert Wessman, will reinvest part of their existing holdings and remain minority shareholders.

Since its founding in 2018, Adalvo has grown rapidly and become a partner to over 170 generic companies in more than 140 countries worldwide. Headquartered in Malta, with more than 280 employees and offices in 15 countries across Europe and India, the Company offers a specialty portfolio, driving affordable health outcomes for patients globally. With increasing demand for effective treatments across indications and therapeutic areas, Adalvo is well-positioned for continued expansion.

EQT will invest in the next phase of Adalvo's growth journey through targeted investments in R&D, supply chain, and operational excellence. This will help expand its product portfolio with a steady cadence of new launches, expand the robust supply chain to cover a wide range of partners and jurisdictions, and enhance business development opportunities for its partners through greater flexibility, reach, and speed to market.

Matteo Thun, Partner within EQT Private Capital's Advisory Team, said: "EQT is deeply impressed by Adalvo's competitive position in dossier development, with an agile and scalable model for development and partnerships with leading pharmaceutical companies globally. We look forward to joining forces with the entrepreneurial and highly respected management team, led by CEO Anil Okay, and to investing in the next chapter of continued growth. Looking ahead, we are committed to supporting Adalvo and its employees in its pivotal role to provide access to affordable healthcare to patients around the world. We are impressed by what Adalvo has achieved under Róbert Wessman's ownership, and are delighted that he will also be part of the next phase of the journey as a minority shareholder."

Anil Okay, CEO of Adalvo, added: "Over the past seven years, we've built a dynamic and innovative platform that supports our partners globally and delivers better healthcare outcomes. We're excited to welcome EQT as a strategic partner, whose long-term vision, cultural alignment, and demonstrated track record in healthcare make them an ideal match to support Adalvo's continued expansion. We remain committed to advancing Adalvo's intrinsic purpose of making affordable medicines accessible to patients around the world."

Róbert Wessmann, Founder & Chairman of Aztiq, commented: "Like all other companies we have founded, Adalvo has been focused on meeting the growing demand globally for better access to high-quality, yet affordable medications. When we founded Adalvo together in 2018 our vision was to revolutionize the important business-to-business segment of the pharmaceutical industry and enable our partners world-wide to meet this growing demand. I am immensely proud of what Adalvo, and its leadership team have achieved in such a short period of time. I would like to congratulate EQT on the acquisition of this amazing company, and am confident that under their stewardship, Adalvo will continue to flourish and achieve even greater success. I look forward to working with EQT on advancing Adalvo's mission, as a minority shareholder"

The transaction is subject to customary conditions and approvals. It is expected to close during H2 2025.

With this transaction, EQT X is expected to be 55 - 60 percent invested (including closed and/or signed investments, announced public offers, if applicable, and less any expected syndication).

Contact
EQT Press Office, press@eqtpartners.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-to-acquire-adalvo--a-leading-b2b-dossier-developer,c4208786

The following files are available for download:


     
     https://mb.cision.com/Main/87/4208786/3585125.pdf   PR_EQT acquires
                                                             Adalvo_18.07.25



     
     https://news.cision.com/eqt/i/adalvo,c3457207     
     Adalvo

View original content:https://www.prnewswire.co.uk/news-releases/eqt-to-acquire-adalvo-a-leading-b2b-dossier-developer-302508580.html

Tags

More Like This

Aztiq sells Adalvo to EQT

EQT to Acquire Adevinta's Spanish Online Classifieds Businesses

EQT Private Equity to invest in software companies HVD Group and Next

EQT to acquire Europa Biosite, a distributor of life science products

Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

EQT to acquire WSO2, a leading global provider of digital transformation technologies

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics